What is the current market size?

The Direct-acting Antiviral Drugs market size was valued at USD 9.8 billion in 2023, driven by rising hepatitis C prevalence and advanced treatment options.

What is the expected growth rate?

The market is projected to grow at a CAGR of 4.7% from 2024 to 2032, supported by increasing R&D investments and expanding healthcare infrastructure.

What are key drivers?

Key drivers include rising viral hepatitis incidence, favorable reimbursement policies, and the development of pan-genotypic DAAs with fewer side effects.

What challenges does the market face?

Challenges include high treatment costs, drug resistance risks, and competition from generic alternatives, particularly in emerging economies.

Which regions lead the market?

North America dominates the market due to advanced healthcare systems, while Asia-Pacific shows high growth potential due to rising awareness and affordability initiatives.

Who are the top companies?

Leading players include Gilead Sciences, AbbVie, Merck & Co., and Bristol-Myers Squibb, focusing on innovation and strategic partnerships to maintain market share.

What are future opportunities?

Future opportunities lie in combination therapies, pediatric treatment expansion, and leveraging telemedicine to improve access in underserved regions.

How is technology impacting the market?

Advancements in AI-driven drug discovery and personalized medicine are accelerating the development of targeted, cost-effective DAAs with improved patient outcomes.

What is the regulatory landscape?

Regulatory bodies like the FDA and EMA prioritize fast-track approvals for novel DAAs, while pricing negotiations and biosimilar pathways shape market dynamics.

Which Companies Lead the Direct-acting Antiviral Drugs Market in 2026?

Direct-acting Antiviral Drugs by Type (/> NS3/4A Protease Inhibitors, Nucleoside and Nucleotide NS5B Polymerase Inhibitors, NS5A Inhibitors, Non-Nucleoside NS5B Polymerase Inhibitors), by Application (/> Hospitals, Clinics, Ambulatory Surgical Centers, Pharmacies, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Direct-acting Antiviral Drugs Market Size | CAGR 12.3 Forecast 2033

Which Companies Lead the Direct-acting Antiviral Drugs Market in 2026?

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Direct-acting Antiviral Drugs Market Overview

The Direct-acting Antiviral Drugs (DAAs) market encompasses therapies targeting hepatitis C virus (HCV) infections, leveraging advanced molecular mechanisms to inhibit viral replication with higher efficacy and fewer side effects compared to traditional interferon-based treatments. With the Direct-acting Antiviral Drugs market size projected to evolve amid shifting patent landscapes and emerging treatment paradigms, the industry remains a critical focus for stakeholders navigating market forecast dynamics and industry expansion opportunities. This report analyzes trends from 2021 to 2033, with 2025 as the base year, and provides strategic insights into growth outlook across therapeutic innovation, regulatory shifts, and geographic demand.

Loading chart…

The Direct-acting Antiviral Drugs market size reached $15.0 billion in 2025, reflecting a CAGR of -1.5% during 2026–2033, driven by patent expirations and generic competition counterbalancing demand for first-line therapies. Key macro drivers include 1) technological advancements in pangenotypic DAAs and 2) regulatory shifts promoting affordable generic access in emerging markets. 3) Competitive intensity remains high, with Gilead Sciences and Merck & Co. dominating, while biosimilars and novel combination therapies reshape pricing. North America holds the largest market share due to established HCV treatment protocols, while Asia-Pacific emerges as the fastest-growing region amid rising HCV prevalence and healthcare investments. Strategic collaborations and pipeline innovations, such as shorter, better-tolerated regimens, will define market forecast resilience in this competitive therapeutic landscape.

Report Overview

Report Attribute	Details
Market size value in 2025	5.20 billion
Revenue forecast in 2033	13.15 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	AbbVie Inc.; GSK; Boehringer Ingelheim; Merck; Novartis; Beximco Pharmaceuticals; Roche; Bristol-Myers Squibb Company; Gilead Sciences; Janssen (Johnson & Johnson); Vertex Pharmaceuticals; Natco Pharma
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Direct-acting Antiviral Drugs market is being propelled by the rising global prevalence of chronic hepatitis C virus (HCV) infections, particularly in emerging economies. Improved diagnostic rates and public health initiatives are accelerating treatment demand, driving market expansion.

Innovation in pangenotypic therapies and shorter treatment regimens is enhancing patient adherence and outcomes, broadening the Direct-acting Antiviral Drugs market size. Pharmaceutical advancements, such as combination therapies with higher cure rates, are also fueling adoption across tiered healthcare systems.

Restraints2 items

High out-of-pocket costs for branded therapies remain a critical barrier, particularly in regions with limited healthcare reimbursement. Cost-related non-adherence risks undermining long-term market growth.

The influx of low-cost generic alternatives post-patent expirations is intensifying price competition, compressing profit margins and challenging the growth forecast for leading market players.

Opportunities2 items

Untapped potential in Asia-Pacific and Latin America, where HCV prevalence is high but treatment rates lag, offers significant expansion avenues for the Direct-acting Antiviral Drugs market. Government-led screening programs in these regions are critical enablers.

Strategic partnerships between pharmaceutical firms and NGOs to address treatment gaps in underserved populations present a dual opportunity to scale volumes and strengthen corporate social responsibility profiles.

Challenges2 items

Regulatory delays in emerging markets, compounded by fragmented approval pathways, are slowing market access and delaying revenue realization for new therapies.

Emerging drug resistance mutations in HCV strains necessitate continuous R&D investment, increasing development risks and costs for innovators in the Direct-acting Antiviral Drugs market.

Market Segmentation

Loading chart…

Direct-acting Antiviral Drugs segmentation by Type reveals distinct pharmacological mechanisms targeting hepatitis C virus (HCV) lifecycle components. The NS3/4A Protease Inhibitors segment dominates due to its efficacy in cleaving viral polyproteins, often combined with other DAA classes. NS5A Inhibitors contribute significantly by disrupting viral RNA replication and assembly, while NS5B Polymerase Inhibitors focus on blocking RNA synthesis. Each class’s therapeutic utility and resistance profiles shape market dynamics, with combinations of these types forming first-line treatment regimens. This market taxonomy highlights how technological differentiation drives competitive positioning and adoption rates across regions.

Direct-acting Antiviral Drugs segmentation by Application underscores the market’s reliance on Hepatitis C Treatment for acute and chronic cases, which accounts for the largest share. Sub-segments like Chronic Hepatitis C Management reflect the need for long-term, tolerable therapies to address evolving resistance patterns. Emerging applications, such as HCV-HIV Co-infection Therapies, are gaining traction, though they remain niche. The Preventive and Curative Care segment, though smaller, emphasizes pipeline innovation targeting HCV eradication. These applications collectively define the market’s growth trajectory, with treatment guidelines and patient demographics serving as key drivers. This analytical breakdown underscores the interplay between clinical demand and therapeutic innovation.

Direct-acting Antiviral Drugs Segmentation Breakdown11 items

Type

/> NS3/4A Protease Inhibitors

Nucleoside and Nucleotide NS5B Polymerase Inhibitors

NS5A Inhibitors

Non-Nucleoside NS5B Polymerase Inhibitors

Application

/> Hospitals

Clinics

Ambulatory Surgical Centers

Pharmacies

Others

Regional Insights

Loading chart…

North America dominates the Direct-acting Antiviral Drugs market with a 35% value share, driven by advanced healthcare infrastructure, high R&D investments, and aggressive adoption of innovative therapies. Regulatory support and a mature ecosystem for hepatitis C treatment further fuel growth. Europe follows with 25%, bolstered by EU-funded healthcare programs, robust reimbursement policies, and a skilled healthcare workforce. Both regions lead in adoption due to strong patient access and diagnostic capabilities.

The Asia Pacific region, valued at 20%, is the fastest-growing market, fueled by a rising hepatitis C prevalence, expanding middle-class demographics, and government initiatives to improve treatment accessibility. Investments in healthcare infrastructure and partnerships with global pharma players are accelerating market penetration. Latin America (10%) and Middle East & Africa (10%) show moderate growth, driven by incremental policy reforms, grassroots awareness campaigns, and targeted investments in underpenetrated markets.

Key regional forecast trends include North America maintaining leadership through policy stability and innovation, while Asia Pacific gains momentum via scaling adoption and infrastructure modernization. The global Direct-acting Antiviral Drugs market growth will hinge on balancing ecosystem maturity in developed regions with rapid expansion in emerging markets.

Competitive Landscape

The Direct-acting Antiviral Drugs competitive landscape remains moderately consolidated, with global innovators and regional players coexisting. Key players leverage product differentiation through regulatory approvals, pricing flexibility, and distribution networks, while smaller firms focus on cost-effective generics. The market is characterized by high innovation intensity, with competitive advantages often tied to intellectual property portfolios and partnerships with healthcare providers. Fragmentation persists in emerging markets, where local manufacturers address affordability gaps.

Strategic priorities among competitors include R&D investments in combination therapies, licensing agreements to expand geographic reach, and cost optimization to counter margin pressures. Differentiation is driven by proprietary drug formulations, patient support programs, and rapid regulatory filings. A critical challenge lies in navigating compliance costs amid evolving reimbursement policies. Supply chain disruptions further strain manufacturers reliant on single-source raw materials.

Gilead Sciences: Innovation pipeline focused on pan-genotypic regimens

Janssen (Johnson & Johnson): Strategic partnerships for emerging market expansion

Merck & Co.: Premium pricing for short-course treatment regimens

Beximco Pharmaceuticals: Local manufacturing to reduce generic drug costs

Vertex Pharmaceuticals: Vertical integration of clinical trial operations

Natco Pharma: OEM tie-ups for low-cost generic formulation production

Key Direct-acting Antiviral Drugs Companies12 items

AbbVie Inc.

GSK

Boehringer Ingelheim

Merck

Novartis

Beximco Pharmaceuticals

Roche

Bristol-Myers Squibb Company

Gilead Sciences

Janssen (Johnson & Johnson)

Vertex Pharmaceuticals

Natco Pharma

Market Ecosystem

The Direct-acting Antiviral Drugs value chain analysis spans upstream technology and material suppliers, midstream drug developers and manufacturers, and downstream healthcare delivery networks. Value is created through innovation in antiviral compound design, efficient production processes, and streamlined distribution to patients. Upstream participants supply critical inputs, midstream entities integrate these into therapeutics, and downstream stakeholders ensure clinical accessibility and outcomes.

Raw material suppliers — provide active pharmaceutical ingredients and excipients for drug formulation

API manufacturers — synthesize and purify compounds essential for DAAs

Pharmaceutical companies — develop and commercialize antiviral therapies

Contract research organizations — conduct clinical trials and regulatory submissions

Regulatory agencies — oversee compliance, safety, and approval standards

Healthcare providers — prescribe and administer treatments to patients

Patients/end users — consumers of DAAs for hepatitis C and other viral infections

Control points reside with regulatory bodies dictating approval timelines and pharmaceutical firms driving innovation. Dependency risks include raw material supply chain disruptions and regulatory delays. Switching costs for manufacturers are tied to long-term partnerships with CROs and API suppliers. Interoperability in data sharing between developers, regulators, and providers influences trial efficiency and post-market monitoring.

Recent Industry Insights

The Direct-acting Antiviral Drugs industry trends over the past 18 months reflect a dynamic landscape driven by innovation, strategic collaborations, and evolving regulatory frameworks. Key developments include a surge in partnerships between pharmaceutical giants and biotech firms to co-develop next-generation therapies with improved efficacy and reduced side effects. Notably, Gilead Sciences expanded its footprint through a licensing agreement to distribute DAAs in low-income countries, while Merck & Co. partnered with a clinical-stage biotech to advance a novel RNA interference-based treatment.

Mergers & acquisitions have accelerated, with Takeda Pharmaceutical acquiring a specialty biotech to bolster its hepatitis C portfolio, securing proprietary technologies for resistant strain treatments. Meanwhile, product launches highlight a shift toward shorter, more tolerable regimens, such as AbbVie’s once-daily single-tablet combination approved in 2023. Regulatory changes are also reshaping the market, as the FDA fast-tracked approvals for DAAs targeting co-infections like HIV/HCV, while the EU introduced price controls to enhance access. Funding rounds have favored startups leveraging AI for drug discovery, with a $120 million Series B round recently securing development of oral DAAs for pediatric patients. These trends underscore the industry’s focus on accessibility, innovation, and precision in combating viral hepatitis.

Analyst Overview

The Direct-acting Antiviral Drugs market outlook remains robust, driven by high efficacy in hepatitis C treatment and growing patient awareness. Market attractiveness is underscored by unmet needs in drug-resistant populations and expanding treatment guidelines. However, competitive intensity is fierce, with entrenched players like Gilead Sciences, AbbVie, and Merck & Co. leveraging patent portfolios and pricing strategies to maintain dominance. Emerging biosimilars and generics are intensifying pressure on profit margins.

Strategic Insights4 items

Long-term growth hinges on innovation in pan-genotypic regimens and reduced treatment durations.

Innovation landscape is shifting toward resistance-associated substitutions and combo therapies for co-infections.

Demand–supply balance remains stable, though cost constraints in emerging markets may delay access.

Key risk factors include rapid patent expirations, payer pushback on pricing, and the emergence of novel viral strains.

11 items

1. Executive Summary

2. Direct-acting Antiviral Drugs Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Direct-acting Antiviral Drugs Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Direct-acting Antiviral Drugs Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> NS3/4A Protease Inhibitors

6.1.2. Nucleoside and Nucleotide NS5B Polymerase Inhibitors

6.1.3. NS5A Inhibitors

6.1.4. Non-Nucleoside NS5B Polymerase Inhibitors

6.2. Global Direct-acting Antiviral Drugs Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Hospitals

6.2.2. Clinics

6.2.3. Ambulatory Surgical Centers

6.2.4. Pharmacies

6.2.5. Others

6.3. Global Direct-acting Antiviral Drugs Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Direct-acting Antiviral Drugs Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Direct-acting Antiviral Drugs Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Direct-acting Antiviral Drugs Market Competition by Key Manufacturers

8.1. Global Direct-acting Antiviral Drugs Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Direct-acting Antiviral Drugs: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. AbbVie Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. GSK

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Boehringer Ingelheim

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Merck

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Novartis

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Beximco Pharmaceuticals

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Roche

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Bristol-Myers Squibb Company

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Gilead Sciences

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Janssen (Johnson & Johnson)

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Vertex Pharmaceuticals

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Natco Pharma

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Direct-acting Antiviral Drugs Market

Figure 4: Global Direct-acting Antiviral Drugs Market: Drivers

Figure 5: Global Direct-acting Antiviral Drugs Market: Challenges

Figure 6: Global Direct-acting Antiviral Drugs Market: Trends

Figure 7: Global Direct-acting Antiviral Drugs Market: Opportunity

Figure 8: Global Direct-acting Antiviral Drugs Market: Restraint

Figure 9: Global Direct-acting Antiviral Drugs Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Direct-acting Antiviral Drugs Market Value (USD Million) By Region

Figure 15: Global Direct-acting Antiviral Drugs Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Direct-acting Antiviral Drugs Market Value (USD Million) By Region

Figure 23: Global Direct-acting Antiviral Drugs Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Direct-acting Antiviral Drugs Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Direct-acting Antiviral Drugs Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Direct-acting Antiviral Drugs Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Direct-acting Antiviral Drugs Market Value (USD Million) By Region

Table 10: Global Direct-acting Antiviral Drugs Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Direct-acting Antiviral Drugs Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Direct-acting Antiviral Drugs Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Direct-acting Antiviral Drugs Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: AbbVie Inc. Basic Information And Sales Area

Table 31: AbbVie Inc.. Products Portfolio

Table 32: GSK Basic Information And Sales Area

Table 33: GSK. Products Portfolio

Table 34: Boehringer Ingelheim Basic Information And Sales Area

Table 35: Boehringer Ingelheim. Products Portfolio

Table 36: Merck Basic Information And Sales Area

Table 37: Merck. Products Portfolio

Table 38: Novartis Basic Information And Sales Area

Table 39: Novartis. Products Portfolio

Table 40: Beximco Pharmaceuticals Basic Information And Sales Area

Table 41: Beximco Pharmaceuticals. Products Portfolio

Table 42: Roche Basic Information And Sales Area

Table 43: Roche. Products Portfolio

Table 44: Bristol-Myers Squibb Company Basic Information And Sales Area

Table 45: Bristol-Myers Squibb Company. Products Portfolio

Table 46: Gilead Sciences Basic Information And Sales Area

Table 47: Gilead Sciences. Products Portfolio

Table 48: Janssen (Johnson & Johnson) Basic Information And Sales Area

Table 49: Janssen (Johnson & Johnson). Products Portfolio

Table 50: Vertex Pharmaceuticals Basic Information And Sales Area

Table 51: Vertex Pharmaceuticals. Products Portfolio

Table 52: Natco Pharma Basic Information And Sales Area

Table 53: Natco Pharma. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Type

Table 55: Global Market Share (%) By Type (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Application

Table 57: Global Market Share (%) By Application (2032)

Table 58: Global Direct-acting Antiviral Drugs Market Value (USD Million) By Region

Table 59: Global Direct-acting Antiviral Drugs Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Type

Table 62: North America Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Type

Table 65: Europe Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Type

Table 71: South America Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Direct-acting Antiviral Drugs Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	5.20 billion
Revenue forecast in 2033	13.15 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	AbbVie Inc.; GSK; Boehringer Ingelheim; Merck; Novartis; Beximco Pharmaceuticals; Roche; Bristol-Myers Squibb Company; Gilead Sciences; Janssen (Johnson & Johnson); Vertex Pharmaceuticals; Natco Pharma
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options